GlaxoSmithKline has outlined plans to introduce five new cancer therapies through 2010. Glaxo R&D chief Moncef Slaoui promised that the launch of cervarix, pazopanib, promacta, rezonic and ofatumumab would make a difference to millions of people in the $30 billion a year cancer market, which has been expanding at a rate of 20 percent per year. The pipeline update is good news to Glaxo shareholders who have been buffeted by a strong headwind of bad news about the risks associated with its blockbuster Avandia.
- read the report on Glaxo from the International Herald Tribune
ALSO: A top Glaxo official says that Avandia's market woes have a lot to do with Congressional Democrats who are using it as a political weapon to attack the Republicans and the FDA. Report